Eli Lilly strikes 2nd deal to boost affordable insulin access, this time in Bangladesh

After striking a pact on affordable insulin in Africa late last year, Eli Lilly is now looking to boost access to the essential medicine in Bangladesh.

Lilly has inked a deal with Bangladesh’s International Agencies (IABL) to supply active pharmaceutical ingredient (API) for its human insulin at an undisclosed "reduced price," the Indianapolis-based drugmaker said Monday. The move is part of a bid to increase access and improve insulin affordability for nearly 1 million people with diabetes in Bangladesh by 2030.